DCM
VRTX icon

Dupont Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Dupont Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,406
Closed -$1.55M – 550
2023
Q2 		$1.55M Buy
4,406
+1,803
+69% +$607K 0.08% 120
2023
Q1 		$820K Sell
2,603
-1,322
-34% -$397K 0.04% 239
2022
Q4 		$1.13M Sell
3,925
-1,228
-24% -$374K 0.05% 293
2022
Q3 		$1.49M Buy
5,153
+125
+2% +$36K 0.09% 237
2022
Q2 		$1.42M Sell
5,028
-2,372
-32% -$635K 0.07% 325
2022
Q1 		$1.93M Buy
7,400
+122
+2% +$29K 0.08% 262
2021
Q4 		$1.6M Buy
7,278
+831
+13% +$162K 0.06% 338
2021
Q3 		$1.17M Sell
6,447
-2,700
-30% -$527K 0.04% 487
2021
Q2 		$1.84M Sell
9,147
-24,103
-72% -$5.04M 0.04% 390
2021
Q1 		$7.14M Sell
33,250
-8,058
-20% -$1.77M 0.17% 96
2020
Q4 		$9.76M Sell
41,308
-9,493
-19% -$2.18M 0.21% 86
2020
Q3 		$13.8M Sell
50,801
-3,223
-6% -$889K 0.3% 64
2020
Q2 		$15.7M Buy
54,024
+3,406
+7% +$923K 0.34% 50
2020
Q1 		$12M Buy
50,618
+6,508
+15% +$1.49M 0.29% 56
2019
Q4 		$9.66M Buy
44,110
+556
+1% +$113K 0.22% 75
2019
Q3 		$7.38M Sell
43,554
-4,215
-9% -$746K 0.17% 107
2019
Q2 		$8.76M Sell
47,769
-12,660
-21% -$2.21M 0.2% 94
2019
Q1 		$11.1M Sell
60,429
-4,835
-7% -$893K 0.25% 77
2018
Q4 		$10.8M Buy
65,264
+923
+1% +$160K 0.26% 67
2018
Q3 		$12.4M Sell
64,341
-5,680
-8% -$1.01M 0.27% 74
2018
Q2 		$11.9M Buy
70,021
+31,049
+80% +$4.81M 0.28% 66
2018
Q1 		$6.35M Sell
38,972
-7,199
-16% -$1.18M 0.15% 131
2017
Q4 		$6.92M Buy
46,171
+2,769
+6% +$410K 0.16% 132
2017
Q3 		$6.6M Buy
43,402
+41,962
+2,914% +$6.32M 0.15% 133
2017
Q2 		$186K Buy
+1,440
New +$173K ﹤0.01% 817
2013
Q3 		– Sell
-52,232
Closed -$4.17M – 645
2013
Q2 		$4.17M Buy
+52,232
New +$3.85M 0.08% 238

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dupont Capital Management's VRTX Position: Q3 2023 in Review

Dupont Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 4,406 shares — an estimated $1.55M sold.

Dupont Capital Management first reported a position in VRTX in Q2 2013 and held it in 26 quarters. The position peaked at $15.7M in Q2 2020. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Dupont Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Dupont Capital Management sold 4,406 Vertex Pharmaceuticals shares in Q3 2023, an estimated $1.55M.
  • Dupont Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Dupont Capital Management's Vertex Pharmaceuticals position peaked at $15.7M in Q2 2020.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Dupont Capital Management's 13F filing for Q3 2023, filed 27 Oct 2023.